A new review synthesizes evidence that gut microbiota composition and metabolites such as short-chain fatty acids modulate ...
BioNTech (NasdaqGS:BNTX) and DualityBio reported positive topline results from the DYNASTY-Breast02 Phase 3 trial in HR+/HER2 ...
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination. For pharmacists counseling patients this ...
The conversation has already turned to how melanoma specialists should adopt the medicine — and how widely these novel vaccines can be deployed.
Sierk Poetting, Ph.D., Chief Operating Officer at BioNTech said: “Our partnership with the Victorian Government demonstrates how public-private collaboration can build lasting c ...
Merck and Moderna’s new personalized cancer vaccine paired with the standard of care reduced the risk of recurrence and death ...
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an ...
BioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to ...
An experimental vaccine developed by Merck and Moderna could become the first vaccine of its kind used to treat cancer. Scientists hope it won’t be the last.
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results